5.940USD-1.16%Mkt Cap: 82.49M USDP/E: —Last update: 2026-05-26
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides pe…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap82.49M USD
Enterprise Value80.59M USD
Revenue (TTM)57.95M USD
Gross Profit28.55M USD
Net Income (TTM)4.70M USD
Revenue/Share4.199 USD
Last Price5.940 USD
Fiscal Year EndApr 2025
MR QuarterJan 2026
Employees213
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS15870P3073
Valuation
P/E (Trailing)—
P/E (Forward)59.50
PEG—
EV/EBITDA-104.40
EV/Revenue1.39
P/S1.43
P/B19.32
EPS (TTM)-0.18
EPS (Forward)0.10
52W Range
5.50011% of range9.630
52W High9.630 USD
52W Low5.500 USD
Profitability
Gross Margin50.15%
Oper. Margin-1.13%
EBITDA Margin-1.33%
Profit Margin8.26%
ROE124.63%
ROA14.53%
Growth
Revenue Growth-2.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF7.39M USD
CapEx (TTM)389.00K USD
FCF Margin8.12%
FCF Yield5.70%
Net Debt-2.13M USD
Net Debt/EBITDA2.76
Balance Sheet
Debt/Equity1.62
Current Ratio0.98
Quick Ratio0.93
Book Value/Sh0.3080 USD
Cash/Share0.5130 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateAug 12, 2015
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.89M
Float5.19M
Insiders26.67%
Institutions47.75%
Short Interest
Short Ratio12.3d
Short % Float1.23%
Short % Out.0.60%
Shares Short83.70K
Short (prev mo.)81.89K
Technical
SMA 505.961 (-0.4%)
SMA 2006.466 (-8.1%)
Beta0.43
S&P 52W Chg28.31%
Avg Vol (30d)9.18K
Avg Vol (10d)13.36K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—